{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=2", "query": { "intervention": "pembrolizumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T08:57:29.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04840394", "title": "Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "BDB018", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-06-22", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 3, "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840394" }, { "nct_id": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1023, "start_date": "2026-01-19", "completion_date": "2031-10-29", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 14, "location_summary": "Miami Beach, Florida • West Palm Beach, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Edina", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216703" }, { "nct_id": "NCT03631407", "title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Vicriviroc", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-09-24", "completion_date": "2021-06-08", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631407" }, { "nct_id": "NCT04777708", "title": "BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Refractory Hepatocellular Carcinoma" ], "interventions": [ { "name": "Nanoplexed Poly I:C BO-112", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-10-13", "completion_date": "2023-03-13", "has_results": false, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04777708" }, { "nct_id": "NCT03428802", "title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Locally Advanced Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "POLD1 Gene Mutation", "POLE Gene Mutation", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-08", "completion_date": "2027-09-21", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • New York, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428802" }, { "nct_id": "NCT06898970", "title": "Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Angiosarcoma", "Angiosarcoma, Adult" ], "interventions": [ { "name": "Vusolimogene Oderparepvec (VO)", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Varun Monga, MBBS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-01-09", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06898970" }, { "nct_id": "NCT04303169", "title": "Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Gebasaxturev", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Favezelimab + Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ATRA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 146, "start_date": "2020-06-26", "completion_date": "2025-09-24", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04303169" }, { "nct_id": "NCT03419130", "title": "Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "OTHER", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-07-18", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2018-12-07", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03419130" }, { "nct_id": "NCT06236425", "title": "TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Metastatic Squamous Cell Carcinoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum based chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2024-03-14", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06236425" }, { "nct_id": "NCT02603887", "title": "Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Smoldering Plasma Cell Myeloma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-07-20", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-06-07T08:57:29.425Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603887" } ] }